Bioclinica Launches Source Document Manager
Bioclinica has launched Source Document Manager. The solution enables clinical trial sponsors and contract research organizations to collect, de-identify, translate, organize, and manage source documents using a cloud-based application.
Bioclinica Source Document Manager supports online protected health information redaction at the site level with verification by a team of quality control experts and boasts direct integration with an online translation service to translate source documents. Additional features include:
- Structured and guided data collection
- Multilingual platform
- AI-aided redaction
- Query management
- Advanced search capabilities
- Complete audit trail
Bioclinica Source Document Manager can be used as a standalone data collection and storage module to collect and review source documents online, or it can be integrated with an existing EDC system or other data tracking system to send redacted and quality-controlled source documents to their destination.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
